Code : 9345-350307      Created Date : Tuesday, September 15, 2015   Update Date : Wednesday, October 21, 2015    Visit : 1692

World Congress on Medical Physics and Biomedical Engineering, June 7-12, 2015, Toronto, Canada

The report of World Congress on Medical Physics and Biomedical Engineering, June 7-12, 2015, Toronto, Canada by Dr. Nader Riyahi Alam
 
Application Code :
306-0215-0091
 
Created Date : Sunday, August 16, 2015 18:11:00Update Date : Saturday, August 29, 2015 12:08:42
IP Address : 188.226.220.27Submit Date : Saturday, August 29, 2015 12:08:53Email : riahialam@gmail.com
Personal Information
Name : nader
Surname : riyahi alam
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : Professor
Tel : +98-21-88973653
Information of Congress
Title of the Congress : World Congress on Medical Physics and Biomedical Engineering, June 7-12, 2015, Toronto, Canada
Title of your Abstract : Gadolinium Labeled Glycosylated Nanomagnetic Particles as Metabolic Contrast Agents in Molecular Magnetic Resonance Imaging
Country : Canada
From : Sunday, June 7, 2015
To : Friday, June 12, 2015
Abstract(Please copy/paste the abstract send to the congress) : Difficulties in the use, preparation, and cost of radioactively-labeled glycosylated compounds led us to this research and development study of a new gadolinium-labeled glucose compounds that do not have a radioactive half-life or difficulties in its synthesis and utilization. Despite its good resolution, Magnetic Resonance Imaging (MRI) has low sensitivity, therefor, using MRI contrast agents, such as GD-DTPA (Magnevist) will improve tissue discrimination in MRI images.
The purpose of this study is the synthesis and physicochemical characterization of glycosylated gadolinium as metabolic contrast agent for molecular MRI (mMRI). In-vitro T1 relaxivity measurement and signal intensity of the glycosylated compounds has been also performed in comparison with magnevist ( GD-DTPA).
Based on the structure of the 2-fluoro-2-deoxy-D-glucose molecule (FDG), first compound consisting of D-glucose conjugated to a well-known chelator, diethylenetriamine pentaacetic acid (DTPA), was syntheside , labeled with Gd to achieve Gd-DTPA-DG, another comound consisting of gadolinium oxide-based nanoparticle coating of diethyleneglycol conjugated with D-glucose via N,N-carbonyldiimidazole (CDI) mediate reaction, to achieve Gd-DEG-DG, and characterized by various analytical technique, utilizes dynamic light scattering (DLS) to determine the size distribution. The nanoparticle size and morphology were using high resolution transmission electron microscopy (HTEM). In our study, the Gd-DTPA-DG were well defined nanoparticle with size 40 nm in diameter TEM images. While Gd-DEG-DG were 10 nm . The mean hydrodynamic diameter of nanoparticles, as measured by DLS, were 300 nm and 70 nm for GD-DTPA-DG and GDDEG- DG, respectively.
The synthesized GD-DTPA-DG and GD-DEG-DG were shown higher relaxometery rates in vitro relative to magnevist. GD-DEG-DG and GD-DTPA-DG demonstrated shorter T1 than GD-DTPA at the same conectration.
Keywords of your Abstract : MRI, signal intensity, longitudinal relaxation rate, Gd-DTPA, Gd2O3-DEG Nanoparticles
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/25804/Forms/306/acceptace-metabolic-wc2015_1.pdf
The presentation : Oral
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/25804/Forms/306/226 Toronto, Canada-cover_1.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/25804/Forms/306/whole-congress1.pdf
Where has your abstract been indexed? : ISI
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : 2600
Delegates from which countries presented in the congress? : from all around the world e.g, USA, CANADA, FRANCE, GERMANY, ENGLAND, ITALY, GREECE, INDIA, JAPAN, KOREA, CHINA, MALAYSIA etc,...
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : varian, GE, Siemense, etc.
What were the responses to your talking points? Were specific questions or concerns raised? : of course, the presentation were wellcomed to many delegates that we talked about the different aspects of the mMRI drugs in new imagimg methods.
If you met staff members, please list their full names & positions. : Dr molai & Dr Jafary from US and some others from canada, france and asian countries.
Please inform us if there are any follow up actions we need to talk with the members of the congress : we need to have contact with them through me. bcz now im be able to make beneficial relation with the university of toronto, wesren ontario, macmaster and manitoba. from now considering the new era of foreign relation with abroad if the international chancellor would try to ease and support those who have the capabilities for making joint collaboration research with foriegn universities, specially with noirth america's universities, then it would be very useful for the managers, lecturers and the students for introducing their abilities to the world and learning the organized and well defined rersearch jobs form now on, so that the results would be productive orinted in thesis and researches.
Your experiences about the travel processes(Providing ticket, accommodation,...) : the expense of the tocket and the accomodation were so high that one scholar is not be able to afford.
Please give a briefing of your own observations and outcomes of the congress: : it was a freat oppotrnity for me t see the other researchers from other countries are working in my field. now im working on the developing new medicines in cellular and molecular imaging, so i saw that its a hot topic over there such that could be a cost benefited research area i medical imaging for more precise dignostic and terapeutic methods as new terms of teranostic method in collaboration with radiotherapy, nuclear medicine, radiology ad neuroradiology de0partments. The aims would better dignosis and terapeutic monitoring by developing new contrast media materials in medical imaging.

 

Your Comments :
captcha
Close